Bupranolol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Bupranolol
Bupranolol.svg
Systematic (IUPAC) name
(RS)-1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
?
Routes Oral, topical (eye drops)
Pharmacokinetic data
Bioavailability < 10%
Protein binding 76%
Metabolism First pass elimination > 90%
Half-life 2-4 hours (plasma)
Excretion > 88% renal (as carboxybupranolol)
Identifiers
CAS number 23284-25-5 N
ATC code C07AA19
PubChem CID 2475
IUPHAR ligand 550
DrugBank DB08808
ChemSpider 2381 YesY
UNII 858YGI5PIT YesY
KEGG D07590 N
ChEMBL CHEMBL305380 YesY
Chemical data
Formula C14H22ClNO2 
Mol. mass 271.78298 g/mol
 N (what is this?)  (verify)

Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol.

Uses and dosage[edit]

Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia. The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against glaucoma.

Pharmacology[edit]

Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a carboxyl group –, of which 88% are eliminated renally within 24 hours.

Adverse effects, contraindications, interactions[edit]

Adverse effects, contraindications and interactions are similar to other beta blockers.

References[edit]

  • Dinnendahl, V, Fricke, U, ed. (2007). Arzneistoff-Profile (in German) 2 (21 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.